Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Bone Joint J ; 105-B(12): 1321-1326, 2023 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-38035599

RESUMEN

Aims: We aimed to assess the cumulative risk of total hip arthroplasty (THA) from in situ fixation for slipped capital femoral epiphysis (SCFE) after a follow-up of almost 50 years. Methods: In this study, 138 patients with 172 affected hips treated with in situ fixation were evaluated retrospectively. A total of 97 patients (70%) were male and the mean age was 13.6 years (SD 2.1); 35 patients (25%) had a bilateral disease. The median follow-up time was 49 years (interquartile range 43 to 55). Basic demographic, stability, and surgical details were obtained from patient records. Preoperative radiographs (slip angle; SA) were measured, and data on THA was gathered from the Finnish National Arthroplasty Register. Results: The preoperative SA was a mean of 39° (SD 19°). At follow-up, 56 of the patients had undergone THA for a hip previously fixed in situ for SCFE (41%) and 64 of all affected hips had been replaced (37%). Kaplan-Meier analysis gave a median prosthesis-free postoperative survival of 55 years (95% confidence interval (CI) 45 to 64) for the affected hips. In a multivariate analysis, female patients had a two-fold risk for THA (hazard ratio (HR) 2.42 (95% CI 1.16 to 5.07)) and a greater preoperative SA increased the risk of THA (HR 1.03 for every increment of 1° (95% CI 1.01 to 1.05)), while patient age at surgery, slip laterality, stability of slip, or diagnostic delay did not have a statistically significant effect on the risk of THA. Conclusion: SCFE treated primarily with in situ fixation may lead to THA in more than 40% of affected hips at a near 50-year follow-up. This risk is approximately 15-times the reported lifetime risk in the Finnish general population. Female sex and increasing preoperative SA significantly predicted higher risk of THA.


Asunto(s)
Artroplastia de Reemplazo de Cadera , Epífisis Desprendida de Cabeza Femoral , Humanos , Masculino , Femenino , Adolescente , Artroplastia de Reemplazo de Cadera/efectos adversos , Articulación de la Cadera/cirugía , Estudios de Seguimiento , Estudios Retrospectivos , Epífisis Desprendida de Cabeza Femoral/diagnóstico por imagen , Epífisis Desprendida de Cabeza Femoral/cirugía , Diagnóstico Tardío
2.
Asia Pac J Clin Oncol ; 15(5): e79-e90, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31313497

RESUMEN

Residual tumor after curative intent therapy in patients with Ewing's sarcoma is of great clinical significance. Surgeons use the resection margin to indicate the completeness of a surgical excision. However, this margin may be either nonviable/necrotic or viable. This systematic review examines the 5-year event-free survival rate and local recurrence as a function of positive resection margins that are nonviable/necrotic versus those that are viable. Multiple databases were searched using the Ovid interface. After full text screening, 45 articles that reported either margin or postchemotherapy histology and one or more outcomes of interest were identified, and two articles reported on margin and histology simultaneously. An attempt was made to contact the remaining authors and one author was able to provide additional data. The data from the three studies suggest that prognosis in ES depends on both margin involvement and the postchemotherapy histological response simultaneously. However, radiation therapy likely improves local control in patients with inadequate surgical margins, regardless of histological response. This is an area where there is a paucity of evidence that needs to be rectified to ensure that ES patients are provided the highest quality of evidence-based care.


Asunto(s)
Neoplasias Óseas/patología , Márgenes de Escisión , Recurrencia Local de Neoplasia/epidemiología , Sarcoma de Ewing/patología , Neoplasias Óseas/cirugía , Humanos , Incidencia , Recurrencia Local de Neoplasia/patología , Recurrencia Local de Neoplasia/cirugía , Pronóstico , Sarcoma de Ewing/cirugía
3.
Acta Paediatr ; 104(7): 738-45, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-25721807

RESUMEN

AIM: Our aims were to establish the 10-year overall and event-free survival rates among children and adolescents with bone sarcomas in Finland, estimate their respective incidences, evaluate the treatment given and describe the key prognostic factors. METHODS: We included 88 patients of <18 years of age diagnosed with a bone sarcoma during 1991-2005 in this retrospective, nationwide and population-based study. Median follow-up time was 12.2 years (range 5.8-20.3 years) for surviving patients. RESULTS: The overall incidence among children and adolescents was 5.1 per million: 3.6 for osteosarcoma, 1.2 for Ewing's sarcoma and 0.3 for chondrosarcoma. The 10-year event-free and overall survival of those with a localised disease at diagnosis was 69% and 82%, respectively. The overall 10-year survival of those with a metastatic disease at diagnosis was 47%. Prognostic factors for localised disease included an axial versus peripheral primary tumour site in Ewing's sarcoma (p = 0.022) and age at diagnosis in osteosarcoma (p = 0.027). CONCLUSION: The 10-year overall survival of children and adolescents diagnosed with a bone sarcoma in Finland during 1991 to 2005 was very good, at 82% if the disease was localised at diagnosis and 47% if it was metastatic at diagnosis.


Asunto(s)
Neoplasias Óseas/epidemiología , Neoplasias Óseas/terapia , Sarcoma/epidemiología , Sarcoma/terapia , Adolescente , Factores de Edad , Neoplasias Óseas/diagnóstico , Niño , Preescolar , Terapia Combinada , Femenino , Finlandia/epidemiología , Humanos , Incidencia , Lactante , Recién Nacido , Masculino , Pronóstico , Estudios Retrospectivos , Sarcoma/diagnóstico , Tasa de Supervivencia
4.
Acta Oncol ; 52(4): 767-75, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23173760

RESUMEN

BACKGROUND: Ewing's sarcoma family of tumors (ESFTs) are rare bone and soft tissue tumors characterized by specific genetic alterations. Our aim was to carry out a nationwide analysis of ESFT, to survey the treatments used and to report the five-year disease specific and event-free survival rates (EFS and DSS). MATERIAL AND METHODS: The study data was gathered from the Finnish National Cancer Registry and all five University Hospitals and consisted of 76 bone and soft tissue ESFT patients diagnosed during 1990-2009. Their medical records were reviewed and data on their disease, treatments, complications and outcome were analyzed. RESULTS: The five-year EFS and DSS of patients with localized disease at diagnosis (n = 57) were 70% and 60%, respectively. Factors contributing to DSS and EFS were the axial vs. peripheral site of primary tumor and adequate surgical resection of the primary tumor. DSS was also affected by patient's age at diagnosis and the treatment employed. The five-year DSS of patients with metastatic disease at diagnosis (n = 19) was 33% and both preoperative and high dose chemotherapy were associated with improved survival. CONCLUSION: Population-based studies including both bone and soft tissue ESFTs are few. In this nationwide, population-based study on Finnish bone and soft tissue ESFT patients, we find their treatment successful and results comparable to those previously published. Absence of metastases, young age at diagnosis and a peripheral primary tumor site were associated with a better prognosis. It seems that surgical resection of the primary tumor should be performed whenever adequate resection margins can be achieved. The role of high dose chemotherapy merits further studies in this setting.


Asunto(s)
Neoplasias Óseas/epidemiología , Sarcoma de Ewing/epidemiología , Adolescente , Neoplasias Óseas/mortalidad , Neoplasias Óseas/patología , Neoplasias Óseas/terapia , Terapia Combinada , Femenino , Finlandia/epidemiología , Humanos , Masculino , Metástasis de la Neoplasia , Sistema de Registros/estadística & datos numéricos , Sarcoma de Ewing/mortalidad , Sarcoma de Ewing/patología , Sarcoma de Ewing/terapia , Análisis de Supervivencia , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...